| Name | Title | Contact Details |
|---|
Kyn Therapeutics is building a new generation of immuno-oncology therapies targeting powerful immunosuppressive metabolic networks. We envision a future where immunotherapies are the foundation of every cancer patient`s treatment, delivering rapid and durable responses. The Kyn team is composed of drug hunters, translational researchers and entrepreneurs drawn from many of the largest innovators in biotechnology supported by world-class advisors, and is backed by a seasoned board of directors anchored by OrbiMed Healthcare Fund Management and Atlas Venture. Kyn Therapeutics is headquartered in the biotech hub of Cambridge, Massachusetts.
Introducing the most advanced platform for clinical genomic analysis… Solutions for each type of medical use Using data and machine learning to build a more accurate picture of each patient We are passionate about creating bioinformatic solutions that ...
In 2013, co-founders Philip Ross and Sophia Wang formed MycoWorks, a San Francisco-based biomaterials company dedicated to bringing new mycelium-grown materials to the world. MycoWorks` patented Fine Mycelium™ technology, an advanced manufacturing platform and breakthrough in materials science, engineers mycelium during growth to form proprietary, interlocking cellular structures for unparalleled beauty, handfeel, strength and durability. The company`s flagship material- Reishi™ - is a new category of material for the world`s best luxury brands.
Hepion Pharmaceuticals is a biopharmaceutical company focused on the development of pleiotropic drug therapy for treatment of chronic liver disease. T
DiNovo is a distributor of USP <797> <71> <800> compliance products, packaging solutions, and infusion supplies. We are designed to bring innovative products at a low cost to the healthcare market place.